ACTG 303 RISK STATUS INFLUENCE ON DISEASE PROGRESSION

ACTG 303 风险状态对疾病进展的影响

• 批准号: 6274479
• 负责人: Ian Frank
• 金额: $ 2.5万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-04-15 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6274479
• 关键词: 2'3' dideoxycytidine; 2'3' dideoxyinosine; 2'3' dideoxynucleoside; AIDS; AIDS therapy; CD4 molecule; antiAIDS agent; blood cell count; clinical research; combination chemotherapy; disease /disorder proneness /risk; human subject; human therapy evaluation; lamivudine; outcomes research; phenotype; virus load; virus replication; zidovudine

There are 4 purposes of this study: (1) to compate the efficacy of continuing AZT/ddI vs adding 3TC or switching to AZT/3TC. (2) to determine the influence of virus load, CD4+ cell counts, biologic phenotypes and the presence of symptomatic HIV disease on the response to a new therapeutic regimen. (3) to determine the influence of virus load, CD4+, and diologic phenotypes and the presence of symptomatic HIV disease on the kinetics of viral replication. (4) to determine the influence of virus load, CD4, biologic phenotypes, and the presence of symptomatic HIV disease on teh rate of emergence of the 3TC associated resistance mutation at codon 184.

这项研究有4个目的： （1）补充继续AZT/DDI与添加3TC或 切换到AZT/3TC。 （2）确定病毒负荷的影响，CD4+细胞计数， 生物学表型和症状HIV疾病的存在 对新的治疗方案的反应。 （3）确定病毒负荷，CD4+和DIOLOGIC的影响 表型和动力学上有症状的HIV疾病的存在 病毒复制。 （4）确定病毒负荷的影响，CD4，生物表型， 以及有症状的艾滋病毒疾病的出现率 密码子184处的3TC相关抗性突变。